Elena Fonfria
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: May 28, 2025
ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: May 28, 2025
Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations.
Journal: Toxins
Published: March 16, 2023
hiPSC-Derived Neurons Provide a Robust and Physiologically Relevant In Vitro Platform to Test Botulinum Neurotoxins.
Journal: Frontiers in pharmacology
Published: October 15, 2020
Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.
Journal: Toxins
Published: May 25, 2018
A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
Journal: Pharmacology research & perspectives
Published: May 04, 2018
Botulinum neurotoxin A and an engineered derivate targeted secretion inhibitor (TSI) A enter cells via different vesicular compartments.
Journal: Journal of receptor and signal transduction research
Published: September 03, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026